Bardia, Aditya

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science

Cancer Cells and MetastasisCancer Genomics and Diagnostics

Cited by 2,476

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 1,711

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,025

Overall survival with ribociclib plus endocrine therapy in breast cancer

Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,001

Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer

Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 874

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 777

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Gómez Pardo, P., et al. (2023) · The Lancet

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 496

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A. (2016) · JAMA Oncology

Breast Cancer Treatment StudiesEstrogen and related hormone effects

Cited by 396

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Lu, Y.-S., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Cardoso, F., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., et al. (2022) · Clinical Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 287

Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors

Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 247

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., et al. (2024) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 188

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial

Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., et al. (2018) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 72

TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer

Abelman, R. O., Wu, B., Barnes, H., Medford, A., Norden, B., Putur, A., Bitman, E., Thant, W., Liu, T., Weipert, C., et al. (2025) · Clinical Cancer Research

Cancer therapeutics and mechanismsLung Cancer Treatments and Mutations

Cited by 61

LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

Bardia, A., Jhaveri, K., Im, S.-A., Pernas Simon, S., De Laurentiis, M., Wang, S., Martinez, N., Santos Borges, G., Cescon, D. W., Hattori, M., et al. (2023) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 43

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., Lee, K. S., et al. (2021) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 30

Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center

Zubiri, L., Rosovsky, R. P., Mooradian, M. J., Piper-Vallillo, A. J., Gainor, J. F., Sullivan, R. J., Marte, D., Boland, G. M., Gao, X., Hochberg, E. P., et al. (2021) · The Oncologist

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 19